Organon & Co. reported fourth‑quarter 2025 revenue of $1.507 billion, a 5% year‑over‑year decline, and a net loss of $205 million. The decline reflects a 15% drop in the Women’s Health segment, largely driven by a 20% ex‑FX decrease in Nexplanon sales, while General Medicines and Biosimilars showed modest growth, with biosimilars revenue up 11% YoY.
The company’s reported gross margin fell to 49.2% from 56.3% in Q4 2024, a 7.1‑percentage‑point contraction (about 12.6% relative). The margin compression was largely attributable to one‑time manufacturing and supply‑network optimization costs and the lower Nexplanon sales volume, which reduced the company’s high‑margin product mix.
Organon’s non‑GAAP Adjusted earnings per share were $0.63, missing the consensus estimate of $0.74 by $0.11 (approximately 15%). The miss was driven by the combined impact of lower revenue, margin compression, and the one‑time manufacturing costs that weighed on profitability.
For the full year 2026, Organon reiterated guidance of roughly $6.2 billion in revenue and $1.9 billion in Adjusted EBITDA, essentially flat with 2025 performance. The guidance signals management’s confidence that the company can maintain its operating profile despite the current headwinds in Women’s Health and the ongoing investment in manufacturing efficiencies.
Investors reacted negatively to the earnings, citing the EPS miss, revenue shortfall, and margin contraction as key concerns. The market’s focus on these metrics underscores the importance of the company’s ability to control costs and sustain growth in its high‑margin segments.
Management emphasized that the 2025 results were a result of deliberate balance‑sheet strengthening and disciplined expense management, and that the 2026 outlook reflects a continued focus on operational performance and strategic investments in the biosimilar franchise.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.